Literature DB >> 28013483

Spousal hematopoietic stem cell transplantation.

Kazuhiro Ikegame1, Katsuji Kaida2, Satoshi Yoshihara2,3, Kyoko Yoshihara2,3, Shinichi Ishii2, Takayuki Inoue2, Masaya Okada2, Hiroya Tamaki2, Toshihiro Soma2, Yasushi Kusunoki4, Hiroto Kojima4, Hiroh Saji4, Hiroyasu Ogawa2.   

Abstract

We report a pilot series of five patients who received stem cell transplantation (SCT) from a spouse for post-transplant relapse or rejection. The inclusion criterion regarding HLA disparities was three or fewer antigen mismatches in the graft-versus-host direction at the HLA-A, B, and DR loci. Four patients received spousal SCT as a third transplant attempt after post-transplant relapse and one as rescue for graft rejection. The reduced intensity conditioning (RIC) regimen consisted of fludarabine, melphalan, and anti-thymocyte globulin (ATG) with 3 Gy of total body irradiation (TBI) for relapse cases and ATG plus 4 Gy of TBI for the rejection case. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus, methylprednisolone, and mycophenolate mofetil. Peripheral blood stem cells were transplanted. Granulocyte engraftment was achieved in all cases between days 9 and 11 (median, 10) with complete spousal chimerism. In three of the five patients, no acute GVHD was observed, while one case developed grade III GVHD and one case grade IV. All four patients evaluable for the anti-leukemic effect achieved complete remission; however, all relapsed between 106 and 334 day post-transplant, and died between days 152 and 548. We suggest that spousal SCT can be performed as a repetitive SCT using a RIC regimen with low-dose ATG and steroid-containing GVHD prophylaxis.

Entities:  

Keywords:  Graft-versus-host disease; Post-transplant relapse; Reduced intensity conditioning; Spousal transplantation

Mesh:

Substances:

Year:  2016        PMID: 28013483     DOI: 10.1007/s12185-016-2168-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  27 in total

1.  The excellent results of spousal kidney transplantation: experience in a Japanese single center.

Authors:  K Sakai; M Okamoto; T Suzuki; A Yoshizawa; S Nobori; H Ushigome; S Sakamoto; K Akioka; S Kaihara; N Yoshimura
Journal:  Transplant Proc       Date:  2008-09       Impact factor: 1.066

2.  Related transplantation with HLA-1 Ag mismatch in the GVH direction and HLA-8/8 allele-matched unrelated transplantation: a nationwide retrospective study.

Authors:  Junya Kanda; Hiroh Saji; Takahiro Fukuda; Takeshi Kobayashi; Koichi Miyamura; Tetsuya Eto; Mineo Kurokawa; Heiwa Kanamori; Takehiko Mori; Michihiro Hidaka; Koji Iwato; Takashi Yoshida; Hisashi Sakamaki; Junji Tanaka; Keisei Kawa; Yasuo Morishima; Ritsuro Suzuki; Yoshiko Atsuta; Yoshinobu Kanda
Journal:  Blood       Date:  2011-10-31       Impact factor: 22.113

3.  Successful treatment of refractory T-cell acute lymphoblastic leukemia by unmanipulated stem cell transplantation from an HLA 3-loci mismatched (haploidentical) sibling.

Authors:  K Ikegame; Y Tanji; N Kitai; H Tamaki; M Kawakami; T Fujioka; Y Oka; E Maruya; H Saji; H Sugiyama; H Ogawa
Journal:  Bone Marrow Transplant       Date:  2003-03       Impact factor: 5.483

4.  Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation.

Authors:  Dao-Pei Lu; Lujia Dong; Tong Wu; Xiao-Jun Huang; Mei-Jie Zhang; Wei Han; Huan Chen; Dai-Hong Liu; Zhi-Yong Gao; Yu-Hong Chen; Lan-Ping Xu; Yao-Chen Zhang; Han-Yun Ren; Dan Li; Kai-Yan Liu
Journal:  Blood       Date:  2005-12-27       Impact factor: 22.113

5.  Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.

Authors:  Hiroyasu Ogawa; Kazuhiro Ikegame; Satoshi Yoshihara; Manabu Kawakami; Tatsuya Fujioka; Tomoki Masuda; Yuki Taniguchi; Hitomi Hasei; Katsuji Kaida; Takayuki Inoue; Eui Ho Kim; Ichiro Kawase
Journal:  Biol Blood Marrow Transplant       Date:  2006-10       Impact factor: 5.742

6.  Spousal renal donor transplantation in Chinese subjects: a 10 year experience from a single centre.

Authors:  Sydney Tang; Sing Leung Lui; Chi Yuen Lo; Wai Kei Lo; Ignatius K P Cheng; Kar Neng Lai; Tak Mao Chan
Journal:  Nephrol Dial Transplant       Date:  2004-01       Impact factor: 5.992

7.  Transplantation of ABO-incompatible and living unrelated donor-recipient combinations.

Authors:  N Ishikawa; T Yagisawa; Y Sakuma; T Fujiwara; A Nukui; M Yashi; N Miyamoto
Journal:  Transplant Proc       Date:  2008-09       Impact factor: 1.066

8.  Recovery from established graft-vs-host disease achieved by bone marrow transplantation from a third-party allogeneic donor.

Authors:  Yuki Taniguchi; Satoshi Yoshihara; Yoshihiko Hoshida; Takayuki Inoue; Tatsuya Fujioka; Kazuhiro Ikegame; Manabu Kawakami; Tomoki Masuda; Katsuyuki Aozasa; Ichiro Kawase; Hiroyasu Ogawa
Journal:  Exp Hematol       Date:  2008-07-02       Impact factor: 3.084

9.  High survival rates of kidney transplants from spousal and living unrelated donors.

Authors:  P I Terasaki; J M Cecka; D W Gjertson; S Takemoto
Journal:  N Engl J Med       Date:  1995-08-10       Impact factor: 91.245

10.  Effect of major histocompatibility complex haplotype matching by C4 and MICA genotyping on acute graft versus host disease in unrelated hematopoietic stem cell transplantation.

Authors:  Yongjung Park; June-Won Cheong; Myoung Hee Park; Myoung Soo Kim; Jong Sun Kim; Hyon-Suk Kim
Journal:  Hum Immunol       Date:  2015-11-18       Impact factor: 2.850

View more
  1 in total

1.  Allogeneic hematopoietic stem cell transplantation from a 2-HLA-haplotype-mismatched family donor for posttransplant relapse: a prospective phase I/II study.

Authors:  Kazuhiro Ikegame; Katsuji Kaida; Keiko Fukunaga; Yuko Osugi; Kyoko Yoshihara; Satoshi Yoshihara; Shinichi Ishii; Satoshi Fujino; Takaya Yamashita; Azusa Mayumi; Satoshi Maruyama; Masahiro Teramoto; Takayuki Inoue; Masaya Okada; Hiroya Tamaki; Hiroyasu Ogawa; Yosihiro Fujimori
Journal:  Bone Marrow Transplant       Date:  2020-06-20       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.